關(guān)鍵詞： Celgene 氘修飾藥物
2013年5月7日訊 /生物谷BIOON/ --賽爾基因（Celgene）昨日宣布,，與Concert制藥達(dá)成了氘化藥物（Deuterium Drug）開(kāi)發(fā)合作,。
根據(jù)協(xié)議，Celgene將利用Concert制藥的氘化化學(xué)實(shí)體（deuterated chemical entity,，DCE）平臺(tái),，創(chuàng)造新的氘修飾（deuterium-modified ）小分子化合物，靶向癌癥和炎癥靶標(biāo),。
Celgene已同意支付一筆預(yù)付款,。此外，若Celgene同意進(jìn)一步開(kāi)發(fā)基于DCE的藥物,，Concert制藥將有資格從每一個(gè)開(kāi)發(fā)項(xiàng)目中收獲總額超過(guò)3億美元的開(kāi)發(fā),、監(jiān)管、銷(xiāo)售里程碑款項(xiàng),，以及每一個(gè)項(xiàng)目所開(kāi)發(fā)藥物在未來(lái)銷(xiāo)售的分層特許權(quán)使用費(fèi),。
氘（deuterium）是氫（hydrogen）的同位素，原子質(zhì)量是后者的2倍,，與碳（carbon）的結(jié)合更強(qiáng),。
Concert制藥成立于2006年，目標(biāo)是將其DCE技術(shù)應(yīng)用于已獲批的藥物及已知人類(lèi)藥理活性的制劑,，來(lái)創(chuàng)造療效更強(qiáng),、耐受性更好、安全性更高的新藥物,。
Concert制藥開(kāi)發(fā)管線包含針對(duì)各種疾病的化合物,，其中走的最遠(yuǎn)的是CTP-499，該藥是糖尿病腎臟疾病的候選藥物,，目前處于II期臨床開(kāi)發(fā),。（生物谷bioon.com）
英文原文：
Celgene, Concert in $300M+ Deuterium Drug Collaboration
Celgene will use Concert Pharmaceuticals’ deuterated chemical entity (DCE) Platform? technology to create new deuterium-modified small molecule compounds targeting cancer and inflammation, in a collaboration that could net the latter more than $300 million.
In return for using the DCE technology, Celgene agreed to give Concert an up-front payment. And if Celgene exercises its options and agrees to develop DCE-based drugs, Concert will be eligible for more than $300 million in payments tied to development, regulatory, and sales milestones for each program selected for development by Celgene. In addition, Concert will receive tiered royalties on any product sales for each of the programs advanced by Celgene.
Founded in 2006, Concert seeks to apply its DCE technology to approved drugs and other agents with known human pharmacological activity, with the goal of creating new medicines that the company says have potential for enhanced efficacy, better tolerability and improved safety. Deuterium is an isotope of hydrogen with twice its atomic mass, allowing for stronger bonding with carbon, yet according to the company it has yet to be systematically studied for its safety and efficacy in medicines.
“Celgene’s deep experience developing clinically meaningful therapies, and their global commitment to patients across multiple therapeutic areas, make them an ideal partner,” Roger Tung, Ph.D., Concert’s president and CEO, said in a statement. “We look forward to working with Celgene to evaluate the potential benefits of deuterium-modification for a number of programs emerging in our pipeline.”
Concert’s pipeline includes compounds for a variety of disorders. Furthest along is CTP-499, a diabetic kidney disease drug candidate now in Phase II development.
Next furthest along in the pipeline is AVP-786, a Phase I neurologic disorders drug candidate being developed with Avanir Pharmaceuticals under an undisclosed but reportedly $200 million-plus collaboration announced last year. Also in Concert’s pipeline are CTP-3534 for spasticity and neuropathic pain; C-10068 for epilepsy and depression; D-Ivacaftor for cystic fibrosis and COPD; and D-Praziquantel, now in a research phase for schistosomiasis.
The collaborations with Avanir and now Celgene mark two of three partnerships Concert has entered into in the past 15 months. The other collaboration, announced February 26, combines Concert with Jazz Pharmaceuticals in the development of narcolepsy drug C-10323, now in a preclinical phase, also for an undisclosed sum but including what several news accounts reported as $120 million in milestone and royalty payments.
(責(zé)任編輯：jie.jiang)
